Angiology · 2010 · 93 citations · 14 references
MedicineBiotechnologyCell TherapyRegenerative MedicineStem Cell BiologyAngiogenesisCritical Limb IschemiaMesenchymal Stem Cell TherapyMesenchymal Stromal Cell TherapyVascular RegenerationBone Marrow - Derived CellsCombination Cell TherapyCombination TherapyEndothelial Progenitor Cell TherapyEndothelial Progenitor CellsLimb Ischemia ManagementLower Limb IschemiaStem Cell-based Therapy
The infusion of a source of endothelial progenitors (EPCs) to limb ischemia (LB) patients has been used to increase angiogenesis. Because the formation of new blood vessels involves, in addition to EPCs, other cells and angiogenic regulators, we postulate that a combination cell therapy including EPCs and mesenchymal stem cells (a source of pericytes progenitors and angiogenic regulators) may represent a preferential stimuli for the development of blood vessels. In this phase I clinical trial, patients with LI were infused with a cell product consisting of autologous bone marrow-derived mononuclear and mesenchymal stem cells. After 10 2 months of follow-up, efficacy assessment demonstrated improvements in walking time, ankle brachial pressure, and quality of life. Concomitantly, angiographic and 99mTc-TF perfusion scintigraphy scores confirmed increased perfusion in the treated limbs. These results show that the use of a combination cell therapy is safe, feasible, and appears effective in patients with LI.
14
Multilineage Potential of Adult Human Mesenchymal Stem Cells
Mark F. Pittenger, Alastair M. Mackay, Stephen C. Beck et al. · Science · 1999 · 21.1K citations
Eriko Tateishi-Yuyama, Hiroaki Matsubara, Toyoaki Murohara et al. · The Lancet · 2002 · 1.7K citations
Dimas Tadeu Covas, Rodrigo Alexandre Panepucci, Aparecida Maria Fontes et al. · Experimental Hematology · 2008 · 602 citations · Full text